|
業務類別
|
-- |
|
業務概覽
|
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment. |
| 公司地址
| 8-1 Akashi-cho, Tokyo, JPN |
| 電話號碼
| -- |
| 傳真號碼
| -- |
| 公司網頁
| http://www.snbl.co.jp |
| 員工數量
| 1114 |
| Ms. Kyomi Nagatoshi |
Director and Senior Managing Director |
-- |
27/06/2025 |
| Dr. Ichiro Nagata |
Director, Executive Vice President and General Manager of Global Services and Communications |
-- |
27/06/2025 |
| Dr. Hideshi Tsusaki |
Director, Senior Managing Director and General Manager of European and American Sales Division |
-- |
27/06/2025 |
| Dr. Ryoichi Nagata |
Chairman of the Board, President, Chief Executive Officer and Chief Health Officer |
-- |
27/06/2025 |
| Mr. Ken Takanashi |
Director and Vice President |
-- |
27/06/2025 |
| Mr. Takashi Iriyama |
Director, Senior Managing Director, Chief Financial Officer and Head of Business Strategy Division |
-- |
27/06/2025 |
|
|
| Ms. Kyomi Nagatoshi |
Director and Senior Managing Director |
27/06/2025 |
| Mr. Tsuyoshi Hanada |
Independent Director |
27/06/2025 |
| Mr. Shinichi Fukumoto |
Independent Director |
27/06/2025 |
| Mr. Takashi Yamashita |
Independent Director |
27/06/2025 |
| Dr. Ichiro Nagata |
Director, Executive Vice President and General Manager of Global Services and Communications |
27/06/2025 |
| Dr. Hideshi Tsusaki |
Director, Senior Managing Director and General Manager of European and American Sales Division |
27/06/2025 |
| Dr. Ryoichi Nagata |
Chairman of the Board, President, Chief Executive Officer and Chief Health Officer |
27/06/2025 |
| Ms. Keiko Toya |
Independent Director |
27/06/2025 |
| Mr. Ken Takanashi |
Director and Vice President |
27/06/2025 |
| Ms. Yumi Hirose |
Independent Director |
27/06/2025 |
| Ms. Chizuru Matsueda |
Independent Director |
27/06/2025 |
| Mr. Takashi Iriyama |
Director, Senior Managing Director, Chief Financial Officer and Head of Business Strategy Division |
27/06/2025 |
|
|
|
|
